Uncategorized Archives - Page 4 of 146

WednesdayOct 08, 2025 10:30 am

Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability

Oncotelic Therapeutics developed the Deciparticles(TM) technology to improve the bioavailability of drugs, largely thanks to the creation of sub-20nm size of the nanoparticles Sapu Nano, part of Oncotelic’s GMP Bio joint venture, receives clearance to begin Phase 1 trial of Sapu003, an injectable form of Everolimus (Afinitor(R)) for breast cancer In preclinical studies, Sapu003 could raise the bioavailability of Everolimus (Afinitor(R)) from around 10%, as oral pill, up to anywhere from 80 to 100%, as injectable Result hopes for higher bioavailability in that drugs may have dramatically better, faster, and more consistent efficacy for patients Oncotelic Therapeutics (OTCQB: OTLC) is a…

TuesdayOct 07, 2025 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study

HeartBeam is developing a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems. The VALID-ECG study results carry significant weight for both clinical adoption and HeartBeam’s commercialization pathway. Early and accurate detection of heart rhythm problems can mean the difference between life-saving intervention and a missed opportunity, which is why new advances in cardiac diagnostics carry such weight. HeartBeam (NASDAQ: BEAT) has reported promising results…

TuesdayOct 07, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision enables re-filing of an Abbreviated New Drug Application (“ANDA”) for the company’s KETAFREE(TM) product, which the company has now done. Current ketamine formulations use multidose vials with a toxic preservative, Benzethonium Chloride. U.S. ketamine market is estimated at $750 million annually, presenting a significant commercial opportunity. NRx is also advancing NRX-100 and NRX-101 for suicidal depression and PTSD, both with FDA designations. The move aligns with U.S. policy goals on reshoring drug production and reducing toxic additives. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company,…

WednesdayOct 01, 2025 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment

Sapu Nano received approval from Australia’s Human Research Ethics Committee (“HREC”) to start enrolling patients in clinical trials for Sapu003 Sapu003 uses Sapu Nano’s Deciparticle(TM) technology to deliver more of the Everolimus drug into the bloodstream, which could be more effective than taking the drug in pill form Sapu Nano is a part of a family of companies formed through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic…

WednesdayOct 01, 2025 9:00 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development

Hoth Therapeutics (NASDAQ: HOTH) is using Lantern Pharma’s (NASDAQ: LTRN) PredictBBB.ai(TM) platform to accelerate development timelines, reduce risk, and improve candidate selection. This technology helps determine whether or not a candidate is able to cross the blood-brain barrier or not, which is a major holdup for many drug development companies. Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the collaboration and how it can help deliver life-changing therapies for patients. Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company…

TuesdaySep 30, 2025 10:30 am

FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy

Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs A recent Type C meeting with the U.S. Food and Drug Administration provided the company with guidance in working through the regulatory pathway and designing the trial for its investigational therapy LP-184/STAR-001, which will seek a means of battling pediatric brain cancers Lantern Pharma is also using drug candidates in trials to combat glioblastoma (“GBM”), triple-negative breast cancer, non-small cell lung cancer in non-smokers, non-Hodgkin’s lymphoma, and…

MondaySep 29, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential

Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option for one of the most prevalent autoimmune skin conditions. The company’s current study aims to further assess safety and biological activity of SGX302, as well as generate additional data to guide larger studies. SGX302 has already demonstrated positive results in a phase 1/2 pilot study. Psoriasis remains a persistent challenge for millions of patients worldwide, and promising new treatments are being closely watched by the medical and investor communities alike. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and inflammatory conditions, is advancing…

FridaySep 26, 2025 12:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Anticipating Tomorrow’s Imaging Standards Today

CMS proposal keeps CT radiation quality measure voluntary, highlighting ongoing debate around dose safety and image quality Izotropic’s IzoView breast CT system engineered to deliver low-dose, high-resolution 3D imaging, aligning with future regulatory and clinical priorities Company launches new FAQ page to enhance transparency for investors, clinicians, and decision-makers In medical imaging, technology often races ahead of regulation. A recent proposal from the Centers for Medicare & Medicaid Services (CMS) underscores this tension: the agency is opting not to mandate radiation dose tracking for CT scans by 2027. While the decision reflects operational challenges hospitals face in meeting such requirements,…

ThursdaySep 25, 2025 9:00 am

Researchers Find That Common Nutrient Could Supercharge the Immune Cells Fighting Cancer

A recently published study by a team at the University of Chicago suggests that a carotenoid called zeaxanthin, naturally occurring in plants like kale, spinach and orange peppers, and well known for its benefits in eye health, could also play a role in supercharging the immune system during the fight against cancer. The research, which appeared in Cell Reports Medicine, indicates that this over-the-counter supplement that is not only affordable but also easily accessible may boost the efficacy of cancer immunotherapies. The study’s senior author, Jing Chen, PhD, explains that the team was surprised when they found that the nutrient…

WednesdaySep 24, 2025 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results

The original FLASH study enrolled 169 patients across three treatment cycles. The ongoing FLASH 2 trial builds on findings found in the first study while addressing regulatory requirements for confirmatory evidence. For Soligenix, the FLASH studies represent more than clinical milestones. These studies are key steps in the company’s regulatory and commercial journey. Soligenix (NASDAQ: SNGX) is continuing to build momentum in its mission to advance HyBryte(TM), a first-in-class treatment for early-stage cutaneous T-cell lymphoma (“CTCL”). That progress is supported by results from its pivotal FLASH trial and its ongoing FLASH 2 confirmatory study. Together, the studies highlight not only the…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability

HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development

FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy

Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Anticipating Tomorrow’s Imaging Standards Today

Researchers Find That Common Nutrient Could Supercharge the Immune Cells Fighting Cancer

Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search